• Corpus ID: 33376969

Urothelial dysplasia of the bladder: diagnostic features and clinical significance.

  title={Urothelial dysplasia of the bladder: diagnostic features and clinical significance.},
  author={Antonio L{\'o}pez-Beltran and Rodolfo Montironi and Alfredo Vidal and Marina Scarpelli and Liang Cheng},
  journal={Analytical and quantitative cytopathology and histopathology},
  volume={35 3},
The 2004 World Health Organization classification system for urothelial neoplasia identifies urothelial dysplasia (low-grade intraurothelial neoplasia) as a premalignant lesion of the urothelium. Although diagnostic criteria of urothelial dysplasia have been improved in recent years, there is a frequent lack of interobserver reproducibility. Follow-up studies suggest that dysplasia is a marker for urothelial instability and disease progression in up to 19% of patients, thus supporting an active… 

Figures and Tables from this paper

Dysplasia and carcinoma in situ of the urinary bladder.

The pathologic features and clinical significance of urothelial dysplasia and carcinoma in situ are presented with emphasis on differential diagnosis from common flat lesions with atypia.

Urothelial Carcinoma in Situ (CIS): New Insights.

Detailed molecular studies have revealed that urothelial CIS may also be divided into luminal and basal subtypes, but luminal subtype is much more common, and it has been shown that in many cases, luminal type of urothalial CIS might undergo a class switch to basal type during progression to an invasive carcinoma.

Utility of CK 20 and micro vessel density in diagnosis and prognosis of urothelial neoplasms

K 20 and MVD are useful in predicting benign versus malignant behavior and defining treatment strategies and can aid the clinician in defining specific targeted therapies.

Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia

K17 is a sensitive and specific biomarker of urothelial neoplasia in tissue specimens and should be further explored as a novel biomarker for the cytologic diagnosis of urine specimens.

Low-Grade Urothelial Neoplasia (LGUN)

The main purpose of this chapter is to review the previously described cytologic criteria of LGPUC in urinary specimens and to define appropriate circumstances that enable the diagnosis of LGUN.

Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm

A novel and “easy to use” algorithm is constructed for a clear, standardized and evidence-based pathological diagnosis of flat non-neoplastic urothelial lesions in order to predict clinical behaviour and allow tailored patient management.

Precursor Lesions of Urologic Malignancies.

The clinical importance and histologic criteria are well established for the known precursor lesions of the most common malignancies throughout the genitourinary tract, but further investigation is warranted at the molecular level to better understand the pathogenesis of these lesions.

Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions: Report From the International Society of Urologic Pathology Consensus Conference

The bladder working group of the 2013 ISUP Conference on Best Practices Recommendation in the Application of Immunohistochemistry (IHC) discussed 5 settings in which IHC is commonly used in clinical practice and found that there is no ideal marker or established panel to confirm urothelial differentiation.

Expression of cancer stem cells markers in urinary bladder urothelial carcinoma and its precursor lesions.

The results showed that studied molecules are not suitable for direct detection of CSC in urothelial carcinoma tissue sections, but an expression of molecules CD24 and CD133 is significantly related to uroclinical carcinoma grade and stage, which are both important prognostic indicators and therefore an expressionof these markers might have a potential prognostic value.



Natural history of urothelial dysplasia of the bladder.

It is concluded that urothelial dysplasia is a significant risk for the development of CIS and invasive urothalial carcinoma, and patients with u rothelial Dysplasia should be followed up closely.

The origins of urothelial carcinoma

Some related issues are discussed, such as the possible role of papillary urothelial hyperplasia as a preneoplastic lesion and the roles of cancer stem cells and field cancerization in u rothelial carcinogenesis.

Clinical Utility of Immunohistochemistry in the Diagnoses of Urinary Bladder Neoplasia

The clinical utility of immunohistochemistry in a series of diagnostic scenarios, including flat urothelial lesions with atypia, rare variants of urothalial carcinoma, primary adenocarcinoma versus secondary colorectal tumors, distinguishing prostate from u rothelial carcinomas, and the utility of smoothelin in staging bladder carcinoma are reviewed.

Morphologic Expressions of Urothelial Carcinoma In Situ: A Detailed Evaluation of Its Histologic Patterns With Emphasis on Carcinoma In Situ With Microinvasion

awareness of the histologic diversity of CIS will facilitate the diagnosis of this therapeutically and biologically critical flat lesion of the urothelium, and may be associated with microinvasion, which may be clinically unsuspected and histologically subtle.

Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation

This paper summarizes the work done by the members of the Committee no. 2 at the International Consultation on the Diagnosis of Non-Invasive Urothelial Neoplasms held in Ancona, Italy, and presents a refined classification of the non-papillary intraepithelial lesions and conditions of the urothelium.

Bladder cancer: Clinical and pathological profile

  • A. López-Beltran
  • Medicine
    Scandinavian journal of urology and nephrology. Supplementum
  • 2008
Emphasis is placed on clinical presentation, the significance of haematuria, macroscopic appearance and synchronous or metachronous presentation of bladder cancer with clinical significance, TNM distribution and the pathological grading according to the 2004 WHO proposal.

The pagetoid variant of bladder urothelial carcinoma in situ

The data suggest that a panel of immunostains including CK7+/CK20+/TM+ may assist in differentiating urothelial pagetoid CIS from extramammary Paget disease which is known to be CK7+.